N-(4-fluoro-3-nitrophenyl)-N-methylcyclohexanecarboxamide | 658700-05-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-fluoro-3-nitrophenyl)-N-methylcyclohexanecarboxamide
• 英文别名: cyclohexanecarboxylic acid (4-fluoro-3-nitrophenyl)(methyl)amide；Cyclohexanecarboxylic acid (4-fluoro-3-nitro-phenyl)-methyl-amide
• CAS: 658700-05-1
• 化学式: C₁₄H₁₇FN₂O₃
• 分子量: 280.299
• InChiKey: ODJMKADPVMHMNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  427.5±35.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-fluoro-3-nitrophenyl)-N-methylcyclohexanecarboxamide 在 palladium on activated charcoal 甲酸铵 、 三乙胺 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 4.0h， 生成 N-[2-amino-1-(3-amino-3-oxopropyl)-1H-benzimidazol-5-yl]-N-methylcyclohexanecarboxamide
  参考文献：
  名称：

  Hit-to-lead studies on benzimidazole inhibitors of ITK: Discovery of a novel class of kinase inhibitors

  摘要：

  Benzimidazole 1 was identified as a selective inhibitor of ITK by high throughput screening. Hit-to-lead studies defined the SAR at all three substituents. Reversing the amide linkage at C6 led to 16, with a fivefold improvement of potency. This enhancement is rationalized by the conformational preference of the substituent. A model for the binding of the benzimidazoles to the ATP-binding site of ITK is proposed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.045
• 作为产物：
  描述：

  4-氟-3-硝基苯胺 在 sodium hydride 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 122.75h， 生成 N-(4-fluoro-3-nitrophenyl)-N-methylcyclohexanecarboxamide
  参考文献：
  名称：

  [EN] NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS
  [FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE COMME INHIBITEURS DE LA FAMILLE DES KINASES TEC

  摘要：

  本发明涉及一种新型的共价激酶抑制剂家族。该类化合物已发现具有对Tec激酶家族成员，特别是ITK、BTK、BMX、Tec和/或RLK的抑制活性。本发明涉及一种具有I式化合物或药用可接受的盐、溶剂化合物、盐的溶剂化合物、立体异构体、互变异构体、同位素、前药、复合物或其生物活性代谢物，并其在治疗中的应用。

  公开号：

  WO2017049401A1

文献信息

• [EN] HETEROCYCLIC AMIDES AS ITK INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS D'ITK
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2014024119A1

  公开（公告）日：2014-02-13

  The present invention is directed to heterocyclic amide compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by ITK.

  本发明涉及异环酰胺化合物的公式(I)，作为Tec激酶抑制剂，特别是ITK（白细胞介素-2诱导酪氨酸激酶）抑制剂。本文还提供了制备所述化合物的方法，用于合成它们的中间体，其药物组合物，以及治疗或预防由ITK介导的疾病、症状和/或紊乱的方法。
• [EN] SUBSTITUTED BENZIMIDAZOLE COMPOUNDS<br/>[FR] COMPOSES BENZIMIDAZOLE SUBSTITUES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004014905A1

  公开（公告）日：2004-02-19

  Disclosed are substituted benzimidazole compounds of formula (I) wherein R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and the pharmaceutical compositions comprising these compounds.

  揭示了一种化学式（I）中的取代苯并咪唑化合物，其中R1、R2、R3、R4和Xa在此处定义。该发明的化合物抑制Itk激酶，因此可用于治疗涉及炎症、免疫紊乱和过敏性疾病的疾病和病理状况。还揭示了制备这些化合物的方法以及包含这些化合物的药物组合物。
• [EN] NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE COMME INHIBITEURS DE LA FAMILLE DES KINASES TEC
  申请人：PHARMASCIENCE INC

  公开号：WO2017049401A1

  公开（公告）日：2017-03-30

  The present invention relates to a novel family of covalent kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the Tec kinase family, particularly ITK, BTK, BMX, Tec and/or RLK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, and its use in therapy.

  本发明涉及一种新型的共价激酶抑制剂家族。该类化合物已发现具有对Tec激酶家族成员，特别是ITK、BTK、BMX、Tec和/或RLK的抑制活性。本发明涉及一种具有I式化合物或药用可接受的盐、溶剂化合物、盐的溶剂化合物、立体异构体、互变异构体、同位素、前药、复合物或其生物活性代谢物，并其在治疗中的应用。
• Substituted benzimidazole compounds
  申请人：Bentzien Martin Joerg

  公开号：US20050203158A1

  公开（公告）日：2005-09-15

  Disclosed are substituted benzimidazole compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 and X a are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

  本发明涉及一种式为(I)的取代苯并咪唑化合物：其中R1、R2、R3、R4和Xa如本文所定义。本发明的化合物抑制Itk激酶，因此可用于治疗涉及炎症、免疫性疾病和过敏性疾病的疾病和病理状态。还公开了制备这些化合物的方法和包含这些化合物的制药组合物。
• Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk)
  作者：Kevin J. Moriarty、Hidenori Takahashi、Steven S. Pullen、Hnin Hnin Khine、Rosemarie H. Sallati、Ernest L. Raymond、Joseph R. Woska、Deborah D. Jeanfavre、Gregory P. Roth、Michael P. Winters、Lei Qiao、Declan Ryan、Renee DesJarlais、Darius Robinson、Matthew Wilson、Mark Bobko、Brian N. Cook、Ho Yin Lo、Peter A. Nemoto、Mohammed A. Kashem、John P. Wolak、André White、Ronald L. Magolda、Bruce Tomczuk

  DOI：10.1016/j.bmcl.2008.09.015

  日期：2008.10

  A series of novel potent benzimidazole based inhibitors of interleukin-2 T-cell kinase (Itk) were prepared. In this report, we discuss the structure-activity relationship (SAR), selectivity, and cell-based activity for the series. We also discuss the SAR associated with an X-ray structure of one of the small-molecule inhibitors bound to ITK. (c) 2008 Elsevier Ltd. All rights reserved.